Diagnostic Test Accuracy of 18 F-FDG PET or PET/CT in Merkel Cell Carcinoma

Clin Nucl Med. 2022 Oct 1;47(10):843-848. doi: 10.1097/RLU.0000000000004321. Epub 2022 Jul 6.

Abstract

Objective: The purpose of the current study was to evaluate the diagnostic accuracies of 18 F-FDG PET or PET/CT for diagnosis of Merkel cell carcinoma (MCC) through a systematic review and meta-analysis.

Methods: The PubMed, Cochrane database, and EMBASE database, from January 1990 to January 31, 2022, were searched for studies evaluating diagnostic performance of 18 F-FDG PET or PET/CT for MCC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.

Results: Across 9 studies (259 patients), the pooled sensitivity of 18 F-FDG PET or PET/CT was 0.91 (95% confidence interval [CI], 0.85-0.95) and a pooled specificity of 0.93 (95% CI, 0.86-0.97). Likelihood ratio syntheses gave an overall LR+ of 14.0 (95% CI, 6.6-29.6) and LR- of 0.09 (95% CI, 0.05-0.17). The pooled diagnostic odds ratio was 153 (95% CI, 57-416).

Conclusion: 18 F-FDG PET/CT showed an excellent performance for diagnosis of MCC. The likelihood ratio scattergram indicated that 18 F-FDG PET or PET/CT is useful for exclusion and confirmation of MCC. Further large multicenter studies would be necessary to substantiate the diagnostic accuracy of 18 F-FDG PET or PET/CT for MCC patients.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Carcinoma, Merkel Cell* / diagnostic imaging
  • Diagnostic Tests, Routine
  • Fluorodeoxyglucose F18
  • Humans
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Sensitivity and Specificity
  • Skin Neoplasms*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18